GalactosemiaMANAGEMENT

ENDOCRINE AND METABOLIC PRESENTATIONS · 12 SECTIONS

⚲

690 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

Acute Porphyria Adrenal crisis Adrenal Insufficiency (Addisonian Crisis)Dehydration Diabetes Insipidus Diabetic Ketoacidosis (DKA)Euglycemic DKA (SGLT2 inhibitor)Galactosemia GLP-1 receptor agonist complications (retained gastric contents, aspiration risk)Homocystinuria Hypercalcemia Hyperkalemia Hypermagnesemia Hypernatremia Hyperosmolar Hyperglycemic State (HHS)Hypertensive emergency Hypertensive urgency Hypocalcemia Hypoglycemia Hypogonadism (Acute Presentation)Hypokalemia Hypomagnesemia Hyponatremia Hypoparathyroidism (Tetany)Insulin pump failure Maple Syrup Urine Disease (Crisis)Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD)Metabolic Acidosis Metabolic Alkalosis Myasthenia gravis crisis Myxedema coma Pellagra Pheochromocytoma (Crisis)Pituitary Apoplexy Pompe Disease (GSD II)Respiratory Acidosis Respiratory Alkalosis Scurvy SIADH Starvation Ketosis Tarui Disease (GSD VII)Thyroid storm Tyrosinemia Vitamin D Deficiency (Severe-Rickets)Von Gierke Disease (GSD I)

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp56

Immediate recognition and stabilization

›Galactosemia metabolic emergency triggers

›Neonate with jaundice + hepatomegaly + E. coli sepsis on milk feeds

›Clinical triad highly suggestive of classic galactosemia Type I

›Treat as galactosemia until proven otherwise

›Symptoms onset within first 1-2 weeks of life after breast milk or lactose-containing formula

›Rapid progression from feeding difficulties to fulminant liver failure

›Can evolve to septic shock within days if untreated

›Immediate cessation of all galactose/lactose-containing feeds

›Switch to soy-based formula without delay

›Do not await confirmatory testing before dietary change

ABC priorities and resuscitation

›Airway and breathing

›Hepatic encephalopathy risk in acute liver failure

›Assess gag reflex and airway protection

›Early intubation if GCS deteriorating

›Respiratory compromise from septic shock

›Supplemental oxygen for SpO2 < 94%

›Escalate to mechanical ventilation if respiratory failure

›Circulation and hemodynamics

›Septic shock management

›IV access (2 large-bore peripheral or intraosseous in neonates)

›Isotonic fluid resuscitation 10-20 ml/kg boluses

›Vasopressor support if refractory hypotension after fluids

›Hypoglycemia correction

›IV dextrose 10% infusion (neonatal standard)

›Target glucose 3.9-6.7 mmol/l

›Continuous glucose monitoring

02History/hx54

Presentation pattern

›Core neonatal syndrome

›Poor feeding and feeding refusal

›Onset after initiation of breast milk or lactose-containing formula

›Typically within first 3-7 days of life

›Vomiting and diarrhea

›Progressive worsening over days

›May resemble pyloric stenosis early

›Lethargy and hypotonia

›Infant progressively less responsive

›Decreased activity after feeds

›Jaundice

›Both unconjugated and conjugated hyperbilirubinemia

›Distinguishes from physiologic jaundice by direct fraction elevation

›Failure to gain weight

›Weight below birth weight beyond day 10

Alarm features

›High-risk historical features

›E. coli neonatal sepsis

›Any neonate with E. coli sepsis requires galactosemia evaluation

›Hallmark early complication

›Cataracts in neonate or infant

›Bilateral oil-droplet cataracts may develop within days to weeks

›May be identified on routine newborn exam

›Coagulopathy or bleeding tendency

›Bleeding from circumcision site or IM injection sites

›Vitamin K-resistant coagulopathy suggests hepatic dysfunction

›Encephalopathy progression

03Physical Exam/exam62

Vitals and general appearance

›Hemodynamic assessment

›Temperature

›Fever suggests concurrent sepsis

›Hypothermia in neonates = severe sepsis marker

›Heart rate

›Tachycardia from sepsis, volume depletion, or fever

›Bradycardia as late sign of decompensation in neonates

›Blood pressure

›Hypotension indicates septic shock

›MAP < 40 mmHg in neonate = critical threshold

›Weight and growth parameters

›Weight loss or failure to regain birth weight

›Length and head circumference for gestational age

Eye examination

›Ophthalmologic findings

›Bilateral cataracts on direct ophthalmoscopy

›Oil-droplet appearance on red reflex exam

›May be present within days of birth

›Slit-lamp examination

›Confirms oil-droplet cataracts

›Cataracts may be reversible with early dietary treatment

›Red reflex abnormality

›Absent or diminished red reflex in affected eye

Abdominal examination

›Hepatic findings

›Hepatomegaly

›Liver edge palpable > 3 cm below costal margin

04Differential Diagnosis/ddx45

Neonatal liver failure differentials

›Metabolic causes of neonatal liver failure

›Galactosemia Type I (classic) — ICD-10 E74.21

›GALT enzyme deficiency, responds to dietary galactose elimination

›E. coli sepsis as distinguishing hallmark

›Tyrosinemia type I — ICD-10 E70.21

›Elevated succinylacetone in urine distinguishes

›Progressive liver and renal tubular dysfunction

›Hereditary fructose intolerance — ICD-10 E74.12

›Triggered by fructose exposure, not lactose

›Symptoms after fruit juice or sucrose introduction

›Mitochondrial hepatopathies

›Elevated lactate, multi-organ involvement

›Normal GALT enzyme activity

Neonatal sepsis and infection differentials

›Infectious causes

›Neonatal sepsis (other organisms) — ICD-10 P36

›E. coli sepsis in galactosemia has metabolic precipitant

›Other gram-negative sepsis lacks metabolic marker

›Herpes simplex virus hepatitis

›Vesicular rash may or may not be present

›Maternal HSV history and CSF PCR

›Cytomegalovirus — ICD-10 P35.1

›CMV IgM, urine CMV PCR

Cholestasis differentials

›Cholestatic jaundice causes

›Biliary atresia — ICD-10 Q44.2

›Conjugated hyperbilirubinemia but no reducing substances

05Laboratory Tests/lt74

Confirmatory metabolic testing

›GALT enzyme activity

›Erythrocyte GALT enzyme activity (gold standard)

›Absent or barely detectable in classic galactosemia

›Must draw BEFORE red cell transfusion

›Heterozygotes have approximately 50% of normal activity

›Erythrocyte galactose-1-phosphate (Gal-1-P)

›Elevated > 0.56 mmol/l (10 mg/dL) in active disease

›Can exceed 6.7 mmol/l (120 mg/dL) in severe cases

›Normal < 0.056 mmol/l (1 mg/dL)

›GALT gene molecular sequencing

›Identifies pathogenic variants

›Most common European variant: p.Gln188Arg

›Preferred if red cell transfusion occurred before testing

Newborn screening

›NBS methodology

›GALT enzyme activity in dried blood spots

›Primary screening method in most US states

›Total galactose (galactose + Gal-1-P) measurement as adjunct

›NBS limitations

›False negative if prior transfusion

›False negative in African Americans with p.S135L (if only total galactose measured)

›Results may return after infant is symptomatic

›Duarte variant detection

›Intermediate enzyme activity approximately 25% of normal

›Confirmed by molecular testing

Urine studies

›Urine reducing substances

06Diagnostic Tests/dt57

Scoring Systems

›Neonatal liver failure severity assessment

›Pediatric End-Stage Liver Disease (PELD) score

›Used for transplant listing prioritization

›Variables: albumin, bilirubin, INR, age, growth failure

›King's College criteria (modified for pediatrics)

›INR > 4 with encephalopathy suggests poor prognosis

›Coagulopathy unresponsive to vitamin K indicates severity

›NASPGHAN severity criteria (2022)

›Acute liver failure = coagulopathy + hepatic encephalopathy

›INR >= 2 without encephalopathy = ALF spectrum

›INR >= 1.5 with encephalopathy = ALF

MRI

›Brain MRI indications

›Long-term neurological complication assessment

›White matter volume loss in classic galactosemia

›Cerebellar atrophy correlating with ataxia severity

›Structural changes despite dietary compliance

›Multiparametric MRI findings (2025 data)

›Myo-inositol deficiency on MR spectroscopy

›Cerebral perfusion alterations

›Correlates with cognitive outcomes

›DEXA scan consideration

›Bone mineral density in older patients

›Decreased bone mineralization despite calcium supplementation

›Annual monitoring from adolescence

›CT imaging role in galactosemia

07Disposition/dispo43

Admission criteria

›NICU admission indications

›Critical neonatal presentation

›Acute liver failure with coagulopathy

›Septic shock or hemodynamic instability

›Encephalopathy or altered mental status

›Hypoglycemia requiring continuous IV dextrose

›Active seizures

›Symptomatic neonates with positive NBS

›Any symptoms warrant inpatient observation

›Dietary change can be managed inpatient while confirmatory testing pending

Transfer criteria

›Transfer triggers

›Pediatric quaternary center indications

›Liver failure not responsive to dietary cessation

›Liver transplant evaluation if fulminant hepatic failure

›No metabolic genetics specialist at receiving facility

›Transfer timing

›Stabilize before transport

›IV access, glucose infusion, antibiotics before transfer

›NICU transport team for critically ill neonates

Outpatient management criteria

›Discharge and outpatient suitability

›Asymptomatic positive NBS

›Immediate dietary switch to soy formula

›Close outpatient follow-up within 24-48 hours

›Family education on galactose restriction

›Established patients on galactose-restricted diet

08Treatment/t82

Acute neonatal crisis management

›Immediate dietary intervention

›Discontinue all galactose/lactose-containing feeds immediately

›Breast milk cessation

›Cow's milk formula cessation

›Switch to soy-based formula (Isomil, Prosobee)

›Soy formula does not contain lactose

›Safe for long-term infant nutrition

›Do not delay dietary change awaiting confirmatory testing

›Clinical diagnosis sufficient to initiate treatment

›Confirmatory testing obtained while on soy formula

Infection management

›Antibiotic therapy for E. coli sepsis

›Ampicillin + gentamicin (standard neonatal sepsis regimen)

›Ampicillin 50 mg/kg IV every 12 hours (< 7 days old)

›Gentamicin 4-5 mg/kg IV every 36-48 hours (neonatal dosing)

›Drug level monitoring required

›Adjust for renal function

›Alternative: ampicillin + cefotaxime

›Cefotaxime 50 mg/kg IV every 12 hours

›Consider in centers with high aminoglycoside resistance

›Duration: 10-14 days for confirmed E. coli sepsis

›Guided by culture results and sensitivities

›Repeat cultures at 48-72 hours

Metabolic and supportive care

›Hypoglycemia management

›Dextrose 10% continuous infusion

›Initial glucose infusion rate 6-8 mg/kg/min in neonates

›Titrate to maintain glucose 3.9-6.7 mmol/l

›Increase rate by 2 mg/kg/min if hypoglycemia persists

›Maximum rate 12-14 mg/kg/min before considering glucagon

›Glucagon 0.02-0.03 mg/kg IM/IV for severe refractory hypoglycemia

›Maximum single dose 1 mg

›Coagulopathy management

›Vitamin K 1 mg IV in neonates

›Repeat daily if INR not correcting

›Oral vitamin K ineffective in cholestasis

›Fresh frozen plasma for active bleeding

›10-20 ml/kg IV over 30-60 minutes

›Target INR < 2 before procedures

›Cryoprecipitate for fibrinogen < 1 g/L with bleeding

›5-10 ml/kg IV

Long-term dietary management

›Lifelong galactose restriction

›Eliminate all dairy products

›Milk, cheese, yogurt, butter, cream

›Hidden lactose in processed foods, medications

›Soy-based nutrition in infancy

›Continue soy formula until 1 year, then transition to soy milk

›Non-dairy calcium sources: fortified soy products, leafy greens

›Acceptable foods in classic galactosemia

›Legumes, some fruits and vegetables (trace galactose tolerated)

›Non-dairy meats, grains, eggs

›Medication review

›Avoid medications with lactose excipients

›Many oral tablets contain lactose as filler

Supplementation

›Micronutrient supplementation

›Calcium supplementation

›500-1000 mg/day elemental calcium depending on age

›Higher risk of bone loss without supplementation

›Vitamin D

›400-1000 IU/day (age-dependent)

›Annual 25-OH vitamin D monitoring

›Vitamin K

›Particularly important in acute neonatal phase

›Ongoing supplementation if cholestasis persists

Hormone replacement therapy

›HRT for premature ovarian insufficiency

›Estrogen replacement in females with POI

›Initiate at expected age of puberty if delayed (age 11-13)

›Estradiol transdermal or oral formulations

›Low dose initiation, titrate to mimic pubertal development

›Add progestogen after uterine priming

›Goals of HRT

›Prevent osteoporosis

›Cardiovascular protection

›Quality of life improvement

Developmental and rehabilitative interventions

›Neurodevelopmental support

›Speech therapy

›Early referral for childhood speech apraxia

›Dysarthria management in older children

›Occupational therapy

›Fine motor skill support

›Activities of daily living assistance

›Physical therapy

›Ataxia and tremor management

›Gait training if cerebellar involvement

09Special Populations/sp58

Pregnancy

›Maternal galactosemia considerations

›Premature ovarian insufficiency prevalence

›Up to 85% of females with classic galactosemia affected

›Spontaneous pregnancy rare but possible

›Fertility consultation prior to conception planning

›Prenatal diagnosis options

›Chorionic villus sampling at 10-13 weeks

›Amniocentesis at 15-20 weeks

›Available when familial GALT pathogenic variants are known

›Pregnancy management in galactosemia

›Continued galactose restriction throughout pregnancy

›HRT discontinuation once pregnancy confirmed

›Close monitoring by maternal-fetal medicine and metabolic genetics

›Neonatal screening urgency

›Infant of affected mother needs immediate NBS

›Soy formula until NBS result returns

›If NBS delayed or unavailable, empiric soy formula

Geriatric

›Older adult considerations

›Long-term complications in adults with galactosemia

›Cognitive decline and intellectual disability variable

›Speech dysarthria and cerebellar ataxia may progress

›Osteoporosis risk increases with age

›Bone health monitoring

›DEXA scan baseline and every 2-5 years

›Calcium 1000-1200 mg/day plus vitamin D 800-1000 IU/day

›Bisphosphonates if osteoporosis confirmed

10Background/b78

Epidemiology

›Incidence and prevalence

›Classic galactosemia Type I incidence

›Approximately 1 in 30,000-60,000 live births in the United States

›Irish Traveller population 1 in 480 births (highest known prevalence)

›Lower prevalence in Asian populations

›Genetic prevalence

›Autosomal recessive disorder

›Carrier frequency approximately 1 in 100-150 in general population

›Homozygous variants required for classic disease

›Variant frequency

›p.Gln188Arg most common European pathogenic variant

›p.S135L most common African American variant (clinical variant galactosemia)

›Over 300 GALT pathogenic variants identified

›Morbidity and mortality

›Untreated neonatal mortality high from sepsis and liver failure

›Dietary treatment prevents acute mortality

›Long-term morbidity persists despite treatment in majority of patients

›Premature ovarian insufficiency in up to 85% of affected females

Pathophysiology

›Enzyme deficiency mechanism

›GALT enzyme deficiency

›GALT catalyzes conversion of galactose-1-phosphate + UDP-glucose to UDP-galactose + glucose-1-phosphate

›Enzyme absent or severely reduced in classic galactosemia

›Galactose-1-phosphate accumulates in tissues

›Galactose-1-phosphate toxicity

›Inhibits phosphoglucomutase and other enzymes

›Accumulates in liver, red blood cells, brain, kidneys, ovaries

›Direct cellular toxicity to hepatocytes causing liver failure

›Galactitol formation

›Alternative metabolism of galactose via aldose reductase

›Galactitol accumulates in lens causing cataracts

›Detected in urine as biomarker

›E. coli susceptibility mechanism

›Galactose-1-phosphate impairs neutrophil bactericidal function

›Complement pathway dysfunction

›Galactose as receptor component for E. coli adhesion

›Long-term pathophysiology

›Endogenous galactose production

›Dietary restriction does not eliminate galactose exposure

›Body produces galactose from UDP-glucose via epimerization

›Explains why neurological complications persist despite diet

›Ovarian toxicity

›Galactose-1-phosphate directly toxic to primordial follicles

›Ovarian damage begins in utero and in early infancy

›Irreversible with current treatments

Therapeutic Considerations

›Current treatment limitations

›Dietary restriction does not prevent all complications

›Long-term neurological complications develop despite adherence

›Speech dysarthria in majority of patients

›Cognitive impairment variable and not fully diet-preventable

›POI occurs even with excellent dietary control

›No pharmacologic cure currently available

›Treatment entirely dietary in standard care

›Emerging investigational therapies

›Emerging therapies under investigation

›GALK1 inhibitors

›Inhibit galactokinase to prevent galactose-1-phosphate formation

›Preclinical data available

›Pharmacological chaperones

›Stabilize misfolded GALT protein

›Applicable to missense variants with residual protein

›mRNA-based therapies

›Replacement of GALT mRNA

›Under early investigation

›Aldose reductase inhibitors

›Prevent galactitol formation

›May reduce cataract formation risk

›ICD-10 classification

›Galactosemia coding

›E74.21 — Galactosemia (GALT deficiency, classic)

›E74.29 — Other disorders of galactose metabolism (GALK, GALE)

›P74.31 — Neonatal hypoglycemia (associated finding)

›Monitoring protocol

›Biochemical surveillance targets

›Erythrocyte Gal-1-P target < 0.56 mmol/l on diet

›Urinary galactitol as complementary dietary compliance marker

›Annual ophthalmology for cataract surveillance

›Annual or biennial bone density from adolescence

›Annual neurodevelopmental and cognitive assessment

11Patient Discharge Instructions/pdi34

copy discharge instructions

›Your child has been diagnosed with galactosemia

›Galactosemia is an inherited condition where the body cannot process galactose (a sugar found in milk products)

›Galactose builds up and causes damage to the liver, brain, and eyes

›This is a lifelong condition requiring permanent dietary changes

›Your child must never eat or drink anything containing milk, lactose, or galactose

›No breast milk, cow's milk, goat's milk, or any milk-based formula

›No cheese, yogurt, butter, ice cream, or dairy products

›Soy-based formula is safe for your baby

›Medications can contain hidden lactose

›Always tell your pharmacist your child has galactosemia before filling any prescription

›Request lactose-free formulations when available

›Your child will need regular follow-up with the metabolic genetics clinic

›Appointments every 3 months in the first year of life

›Blood and urine tests to monitor galactose levels

›Eye exams to check for cataracts

›Return to the emergency department immediately if your child has

›Difficulty feeding or complete refusal to eat

›This may indicate metabolic decompensation

›New yellowing of the skin or eyes (jaundice)

›Suggests liver involvement

›Fever or signs of infection

›Children with galactosemia are at higher risk for serious bacterial infections

›Do not wait — come to the ER immediately

›Unusual sleepiness, limpness, or inability to wake normally

›Suggests low blood sugar or liver failure

›Seizures or abnormal movements

›May indicate low blood sugar or neurological complication

12References/r47

Guidelines and key sources

›Cochrane systematic review on newborn screening for galactosemia

›Lak R, Yazdizadeh B, Davari M, Nouhi M, Kelishadi R

›Newborn Screening for Galactosaemia

›Cochrane Database of Systematic Reviews, 2020

›Basis for NBS recommendations and incidence data

›ACMG Technical Standard and Guideline

›Pasquali M, Yu C, Coffee B

›Laboratory Diagnosis of Galactosemia

›Genetics in Medicine, 2018

›Defines laboratory diagnostic thresholds and enzyme assay protocols

›GeneReviews Classic Galactosemia (Berry GT, 2021)

›Comprehensive clinical management and monitoring protocols

›National Institutes of Health Bookshelf

›Standard reference for long-term management

›Viggiano E, Marabotti A, Politano L, Burlina A

›Galactose-1-phosphate uridyltransferase deficiency mechanisms

›Clinical Genetics, 2018

›Pathophysiology of short and long-term complications

›Neonatal liver failure management

›NASPGHAN Position Paper on Pediatric Acute Liver Failure

›Squires JE, Alonso EM, Ibrahim SH, et al

›Journal of Pediatric Gastroenterology and Nutrition, 2022

›Severity criteria and management framework

›Long-term outcomes evidence

›Succoio M, Sacchettini R, Rossi A, Parenti G, Ruoppolo M

›Galactosemia: Biochemistry, Molecular Genetics, Newborn Screening, and Treatment

›Biomolecules, 2022

Learn More: Galactosemia→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.